Tag: Advocacy

Researchers are developing biomedical repair therapies to address multiple age-related diseases at once, yet they are forced to put them through regulatory pathways built for single-disease drugs. The result is delay, duplication, and unnecessary cost precisely when speed matters the most. The single-disease-indication trap Current regulation still treats age-related diseases as if they were a...

Filmmaker Tim Maupin has spent a number of years developing The Last Generation to Die, a near-future film about what happens when the first true rejuvenation technologies arrive and who gets left behind. The project has now reached the top 65 of the Future Vision XPrize, a global contest seeking optimistic visions of humanity’s future....

Worldwide healthcare faces an unsustainable situation. We spend trillions managing the late-stage effects of biological aging, yet routinely overlook the underlying causes that drive them. Driven by an aging society, the financial burdens of treating diabetes, dementia, and heart disease are pushing Social Security and Medicare towards increasing and potentially catastrophic budget deficits [1]. Treating...

Montana’s first experimental treatment review board has brought three longevity heavyweights into the state’s effort to expand access to experimental therapies. How much regulation is too much? Many people in the longevity field will tell you that regulation is holding it back. Sensible oversight of novel therapies is essential, but an overly cautious interpretation of...

For those of us in the Northern Hemisphere, spring is here. This is a time of renewal and hope for better times ahead, echoing what our field is trying to achieve: the rejuvenation of aging cells and tissues to keep older people free from age-related diseases. On that note, let’s take a look at what...

João Pedro de Magalhães, professor at the University of Birmingham, is known as a prominent geroscientist who has been in the field forever, enriching it with top-tier research. He is also a skilled longevity advocate who has long taken interest in the ethics of longevity, first offering his perspective as far back as 2003. Prof....